The Evolving Landscape of Childhood Histiocytosis: A Decade of Discovery and Innovation
Abstract
1. Introduction
2. Molecular Pathogenesis: A Defining Discovery
3. Reclassifying Histiocytic Disorders
4. Clinical Heterogeneity and Diagnostic Advances
5. Therapeutic Advancements and Targeted Therapy
6. Long-Term Complications and Quality of Life
7. Emerging Concepts and Personalized Medicine
8. Challenges and Future Directions
- Standardizing Molecular Testing: Access to and the standardization of molecular diagnostics is inconsistent globally. Many resource-limited settings lack the infrastructure for next-generation sequencing, hindering diagnosis and trial enrollment;
- Relapse Management: Strategies for managing and preventing relapses, particularly after targeted therapy, require optimization. Longitudinal studies to define the optimal duration of maintenance therapy are needed;
- Understanding CNS Disease: Mechanistic studies on ND-LCH are urgently required. Animal models and longitudinal neuroimaging studies may yield insights into pathogenesis and guide therapeutic development;
- Long-Term Data: Prospective registries are essential to track long-term outcomes and treatment-related toxicities. Registries like Euro-Histio-Net and national databases in the US, France, and Japan are critical for capturing real-world data;
- Equity in Care: Disparities in access to specialized care and molecular diagnostics must be addressed. Telemedicine, international collaboration, and educational initiatives can help to bridge these gaps.
9. Conclusions
Conflicts of Interest
References
- Badalian-Very, G.; Vergilio, J.A.; Degar, B.A.; MacConaill, L.E.; Brandner, B.; Calicchio, M.L.; Kuo, F.C.; Ligon, A.H.; Stevenson, K.E.; Kehoe, S.M.; et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010, 116, 1919–1923. [Google Scholar] [CrossRef] [PubMed]
- Héritier, S.; Emile, J.F.; Barkaoui, M.A.; Thomas, C.; Fraitag, S.; Boudjemaa, S.; Renaud, F.; Moreau, A.; Peuchmaur, M.; Chassagne-Clément, C.; et al. BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. J. Clin. Oncol. 2016, 34, 3023–3030. [Google Scholar] [CrossRef] [PubMed]
- Liu, S.; Zhu, Y.; Chen, Y.; Wang, Y.; Zhang, D.; Zhang, J.; Wang, Y.; Zhang, A.; Hu, Q.; Liu, A. Circulating Tumor DNA Combining with Imaging Analysis for Lesion Detection of Langerhans Cell Histiocytosis in Children. Children 2024, 11, 1449. [Google Scholar] [CrossRef] [PubMed]
- Emile, J.F.; Abla, O.; Fraitag, S.; Horne, A.; Haroche, J.; Donadieu, J.; Requena-Caballero, L.; Jordan, M.B.; Abdel-Wahab, O.; Allen, C.E.; et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood 2016, 127, 2672–2681. [Google Scholar] [CrossRef] [PubMed]
- Gadner, H.; Grois, N.; Arico, M.; Broadbent, V.; Ceci, A.; Jakobson, A.; Komp, D.; Michaelis, J.; Nicholson, S.; Pötschger, U.; et al. A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis. J. Pediatr. 2001, 138, 728–734. [Google Scholar] [CrossRef] [PubMed]
- Gadner, H.; Minkov, M.; Grois, N.; Pötschger, U.; Thiem, E.; Aricò, M.; Astigarraga, I.; Braier, J.; Donadieu, J.; Henter, J.-I.; et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood 2013, 121, 5006–5014. [Google Scholar] [CrossRef] [PubMed]
- Minkov, M.; Steiner, M.; Pötschger, U.; Aricò, M.; Braier, J.; Donadieu, J.; Grois, N.; Henter, J.I.; Janka, G.; McClain, K.; et al. Reactivations in multisystem Langerhans cell histiocytosis: Data of the international LCH registry. J. Pediatr. 2008, 153, 700–705.e2. [Google Scholar] [CrossRef] [PubMed]
- Gadner, H.; Grois, N.; Pötschger, U.; Minkov, M.; Aricò, M.; Braier, J.; Broadbent, V.; Donadieu, J.; Henter, J.I.; McCarter, R.; et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 2008, 111, 2556–2562. [Google Scholar] [CrossRef] [PubMed]
- Diamond, E.L.; Subbiah, V.; Lockhart, A.C.; Blay, J.Y.; Puzanov, I.; Chau, I.; Raje, N.S.; Wolf, J.; Erinjeri, J.P.; Torrisi, J.; et al. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. JAMA Oncol. 2018, 4, 384–388. [Google Scholar] [CrossRef] [PubMed]
- Allen, C.E.; Merad, M.; McClain, K.L. Langerhans-cell histiocytosis. N. Engl. J. Med. 2018, 379, 856–868. [Google Scholar] [CrossRef] [PubMed]
- Berres, M.L.; Lim, K.P.; Peters, T.; Price, J.; Takizawa, H.; Salmon, H.; Idoyaga, J.; Ruzo, A.; Lupo, P.J.; Hicks, M.J.; et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J. Exp. Med. 2015, 212, 281–296. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Aricò, M. The Evolving Landscape of Childhood Histiocytosis: A Decade of Discovery and Innovation. Pediatr. Rep. 2025, 17, 62. https://doi.org/10.3390/pediatric17030062
Aricò M. The Evolving Landscape of Childhood Histiocytosis: A Decade of Discovery and Innovation. Pediatric Reports. 2025; 17(3):62. https://doi.org/10.3390/pediatric17030062
Chicago/Turabian StyleAricò, Maurizio. 2025. "The Evolving Landscape of Childhood Histiocytosis: A Decade of Discovery and Innovation" Pediatric Reports 17, no. 3: 62. https://doi.org/10.3390/pediatric17030062
APA StyleAricò, M. (2025). The Evolving Landscape of Childhood Histiocytosis: A Decade of Discovery and Innovation. Pediatric Reports, 17(3), 62. https://doi.org/10.3390/pediatric17030062